Hong Zhao, Ph.D. CEO Hisun USA
Dr. Zhao received his doctorate in Organic Chemistry from Rutgers University in 1997 and is the author of 35 publications, 33 US issued patents and more than 30 US patent applications. His pharmaceutical experience includes senior research and advisory positions at Enzon Pharmaceuticals and NOF America Corporation. “As a scientist, and the CEO of Hisun USA, I am dedicated to leverage technology and science to develop and bring to market innovative and affordable medications to treat a variety of diseases, including cancer, cardiovascular and neurological diseases. At Hisun we are committed to developing new products for our valued strategic partners and new medications to advance the treatment of disease.”
Hisun USA is dedicated to bringing together science and technology to deliver innovative and affordable medications.
News & Events
- DCAT 2023 02/07/ 2023
- BIO Partnering at JPM 11/28/ 2022
- BIO2022 05/03/ 2022
- CPhI north america 05/03/ 2022